# Gencellmed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gencellmed

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.gencellmed.com
- Total disclosed funding: $5.3M
- Latest round: Series A (Mar 31, 2021)
- Investors on record: 6

## About

Founded in 2019, and based in Seoul, South Korea, Gencellmed, Inc., operates as a developer of various technologies for gene therapy. In March 2021, Gencellmed, Inc., raised KRW 6 billion in series A funding from LSK Investment, DAYLI Partners, Magna Investments, Lighthouse Combined Investment, Innopolis Partners, and KDB Capital. As of 2023, the company is led by its CEO and CTO, Heechung Kwon.

Gencellmed offers a self-targeting adapter and double targeting platform that provide therapeutic solutions for the treatment of cancer. The company uses SMART™ platform technology and therapeutic virus engineering technology that infects disease cells and produces therapeutic viruses that help the patient’s immune system synergize to destroy disease cells.

The company’s pipelined platforms are GCM-101, GCM-201, and GCM-301 used for the treatment of ovarian cancer, and pancreatic cancer, respectively.

## Funding rounds

- Series A, Mar 31, 2021, $5.3M — Innopolis Partners, KDB Capital, Magna Investment, LSK Investment, Lighthouse Combined Investment, DAYLI Partners

## Investors

- Innopolis Partners (https://capitalatlas.ai/funds/innopolis-partners) — Series A
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A
- Lighthouse Combined Investment (https://capitalatlas.ai/funds/lighthouse-combined-investment) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A